KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Treasury Shares: 2013-2024

Historic Treasury Shares for Travere Therapeutics (TVTX) over the last 2 years, with Dec 2024 value amounting to $3.5 million.

  • Travere Therapeutics' Treasury Shares rose 235.85% to $3.2 million in Q4 2014 from the same period last year, while for Dec 2014 it was $3.2 million, marking a year-over-year increase of 235.85%. This contributed to the annual value of $3.2 million for FY2014, which is 235.85% up from last year.
  • Per Travere Therapeutics' latest filing, its Treasury Shares stood at $3.5 million for Q4 2024, which was up 22.38% from $2.9 million recorded in Q4 2023.
  • In the past 5 years, Travere Therapeutics' Treasury Shares registered a high of $3.5 million during Q4 2024, and its lowest value of $1.1 million during Q4 2020.
  • In the last 3 years, Travere Therapeutics' Treasury Shares had a median value of $2.9 million in 2023 and averaged $2.9 million.
  • Data for Travere Therapeutics' Treasury Shares shows a peak YoY spiked of 235.85% (in 2014) over the last 5 years.
  • Quarterly analysis of 2 years shows Travere Therapeutics' Treasury Shares stood at $957,272 in 2013, then surged by 235.85% to $3.2 million in 2014.
  • Its last three reported values are $3.5 million in Q4 2024, $2.9 million for Q4 2023, and $2.3 million during Q4 2022.